Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focusing on creating value for people living with neurology and immunology conditions.
Celebrating 90 years of innovation #UCB90
Twitter Feed
-
You love sharing stories about your kids, so why not tell your own? Post about your journey with chronic inflammatory disease on social using #AIMotherhood or submit our website. https://t.co/DDFeuyPjGK https://t.co/w5MFAycbXa
— UCB News (@ucb_news) 17.08.2018 -
It’s easy to feel lost and stuck with #Osteoporosis. However there are ways to combat that feeling; don’t suffer in silence. Join a support group for help and advice #ACTonFractures #OsteoporosisInsights
— UCB News (@ucb_news) 17.08.2018 -
Women with #psoriasis are more likely to report anticipation of rejection and feelings of being flawed due to stigma than men. #PsoriasisAwarenessMonth #PsoriasisActionMonth https://t.co/anDqLqtd3o
— UCB News (@ucb_news) 16.08.2018
Highlights
UCB Ventures, a strategic corporate venture fund established in 2017 to further strengthen UCB’s ability to create value from novel insights and technologies that can transform the lives of patients suffering from severe diseases, has announced its first direct investment.
